Sumithra J. Mandrekar

18.2k total citations · 4 hit papers
213 papers, 9.4k citations indexed

About

Sumithra J. Mandrekar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sumithra J. Mandrekar has authored 213 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 56 papers in Cancer Research. Recurrent topics in Sumithra J. Mandrekar's work include Lung Cancer Treatments and Mutations (59 papers), Statistical Methods in Clinical Trials (52 papers) and Cancer Genomics and Diagnostics (51 papers). Sumithra J. Mandrekar is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Statistical Methods in Clinical Trials (52 papers) and Cancer Genomics and Diagnostics (51 papers). Sumithra J. Mandrekar collaborates with scholars based in United States, Canada and France. Sumithra J. Mandrekar's co-authors include Daniel J. Sargent, Alex A. Adjei, Jan Bogaerts, Janet Dancey, Lesley Seymour, Patrick Therasse, Lalitha Shankar, Saskia Litière, Nancy U. Lin and Lawrence H. Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sumithra J. Mandrekar

207 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

2017 1.5k citations Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology profile →
RECIST 1.1—Update and clarification: From the RECIST committee

2016 1.2k citations Lawrence H. Schwartz, Saskia Litière et al. profile →
CT Screening for Lung Cancer: Five-year Prospective Experience

2005 481 citations Sumithra J. Mandrekar, Shauna L. Hillman et al. profile →
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020 240 citations Sumithra J. Mandrekar, Lewis R. Roberts et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sumithra J. Mandrekar United States	47	4.3k	3.4k	1.8k	1.4k	1.2k	213	9.4k
Alexia Iasonos United States	51	3.2k 0.7×	2.3k 0.7×	1.6k 0.9×	1.4k 1.0×	662 0.5×	266	10.3k
Rajeshwari Sridhara United States	53	4.8k 1.1×	2.9k 0.8×	3.0k 1.7×	1.3k 1.0×	484 0.4×	137	9.3k
Patricia Keegan United States	54	5.0k 1.1×	3.1k 0.9×	2.1k 1.2×	1.6k 1.2×	384 0.3×	140	9.3k
B. Nebiyou Bekele United States	56	3.8k 0.9×	3.3k 1.0×	3.9k 2.2×	1.4k 1.0×	628 0.5×	137	10.3k
Sin‐Ho Jung United States	47	2.7k 0.6×	1.8k 0.5×	1.6k 0.9×	602 0.4×	1.2k 1.0×	299	8.1k
Gary L. Rosner United States	52	3.0k 0.7×	1.5k 0.5×	2.9k 1.6×	1.4k 1.0×	1.3k 1.1×	207	9.1k
Robert J. Gray United States	48	7.4k 1.7×	4.8k 1.4×	3.0k 1.7×	4.4k 3.2×	1.3k 1.1×	173	14.3k
Stefan Michiels France	53	6.9k 1.6×	2.9k 0.9×	3.7k 2.1×	3.8k 2.7×	697 0.6×	265	12.2k
Eitan Amir Canada	57	8.8k 2.0×	3.9k 1.1×	2.6k 1.4×	3.6k 2.6×	400 0.3×	416	15.4k
Kristine Broglio United States	52	7.2k 1.6×	2.6k 0.8×	1.9k 1.1×	4.3k 3.1×	437 0.4×	148	12.3k

Countries citing papers authored by Sumithra J. Mandrekar

Since Specialization

Citations

This map shows the geographic impact of Sumithra J. Mandrekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumithra J. Mandrekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumithra J. Mandrekar more than expected).

Fields of papers citing papers by Sumithra J. Mandrekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumithra J. Mandrekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumithra J. Mandrekar. The network helps show where Sumithra J. Mandrekar may publish in the future.

Co-authorship network of co-authors of Sumithra J. Mandrekar

This figure shows the co-authorship network connecting the top 25 collaborators of Sumithra J. Mandrekar. A scholar is included among the top collaborators of Sumithra J. Mandrekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumithra J. Mandrekar. Sumithra J. Mandrekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaz-Luís, Inês, Graziella Mazza, Angela DeMichele, et al.. (2025). 485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC). Annals of Oncology. 36. S378–S378. 1 indexed citations

Zahrieh, David M., Carrie Strand, Paul J. Limburg, Aminah Jatoi, & Sumithra J. Mandrekar. (2025). Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials. Cancer Prevention Research. 19(1). 11–23.

Prindiville, Sheila A., Sumithra J. Mandrekar, Neal J. Meropol, et al.. (2024). Streamlining the conduct of cancer clinical trials: new standard data collection practices for National Cancer Institute late-phase clinical studies. JNCI Journal of the National Cancer Institute. 117(3). 396–401. 1 indexed citations

Rutherford, Sarah C., Jun Yin, Levi Pederson, et al.. (2024). Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma. Blood Advances. 8(6). 1464–1468. 2 indexed citations

Jacobson, Jeffrey M., David M. Zahrieh, Carrie Strand, et al.. (2022). Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevention Research. 16(3). 163–173. 11 indexed citations

Adjei, Alex A., Sai‐Hong Ignatius Ou, Cheryl Ho, et al.. (2021). Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships. Journal of Thoracic Oncology. 16(5). 706–708.

Sands, Jacob, Sumithra J. Mandrekar, David Kozono, et al.. (2021). Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO). Immunotherapy. 13(9). 727–734. 17 indexed citations

Le‐Rademacher, Jennifer, Camden Lopez, Eric Wolfe, et al.. (2020). Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. Journal of Cachexia Sarcopenia and Muscle. 11(6). 1501–1508. 24 indexed citations

Mandrekar, Sumithra J., et al.. (2020). Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials. Journal of Cancer Education. 36(6). 1248–1252. 7 indexed citations

10.

Seymour, Lesley, Jan Bogaerts, Andrea Perrone, et al.. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 18(3). e143–e152. 1528 indexed citations breakdown →

11.

Yan, Fangrong, Sumithra J. Mandrekar, & Ying Yuan. (2017). Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research. 23(15). 3994–4003. 108 indexed citations

12.

Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, et al.. (2015). Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(7). 1099–1106. 33 indexed citations

13.

Zhao, Yujie, Nathan R. Foster, Jeffrey P. Meyers, et al.. (2014). A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology. 10(1). 172–180. 38 indexed citations

14.

Reid, Joel M., Chad A. Walden, Rui Qin, et al.. (2011). Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prevention Research. 4(3). 347–353. 16 indexed citations

15.

An, Ming-Wen, Sumithra J. Mandrekar, Megan E. Branda, et al.. (2011). Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials. Clinical Cancer Research. 17(20). 6592–6599. 22 indexed citations

16.

Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations

17.

Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations

18.

Adjei, Araba A., Grace K. Dy, Sumithra J. Mandrekar, et al.. (2007). PD2-3-5: Pemetrexed pharmacogenomics: haplotype analyses of transport and activation/inactivation gene polymorphisms and the therapeutic outcome in non-small cell lung cancer, an NCCTG N0026 based study. Journal of Thoracic Oncology. 2(8). S445–S445. 1 indexed citations

19.

Haluska, Paul, Joan M. Carboni, David A. Loegering, et al.. (2005). BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines. Cancer Research. 65. 1191–1191. 2 indexed citations

20.

Mandrekar, Sumithra J., Haikady N. Nagaraja, & Gary G. Berntson. (2004). Statistical modelling of the differences between successive R-R intervals. Statistics in Medicine. 24(3). 437–451. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact